<DOC>
	<DOC>NCT01612273</DOC>
	<brief_summary>To explore the efficacy of triflusal in patients with symptomatic peripheral microcirculation dysfunction. Triflusal is a salicylate compound approved in several countries as antithrombotic agent and it additionally has vasodilatory effect. The hypothesis is to explore if there is a improvement of peripheral microcirculation by triflusal.</brief_summary>
	<brief_title>The Effect of Triflusal on Peripheral Microcirculation Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Triflusal</mesh_term>
	<criteria>Between 40 and 70 years of age Diagnosed vasospastic syndrome with nailfold capillaroscopy (Fingertip is subjected to carbon dioxide at 15Â°C for 60 seconds. People found to have a bloodflow standstill of at least 12s in one or more capillaries were defined as having vasospasticity) More than seven points in 10question interview provided by Nagashima et al. Written informed consent Prior documented diabetes Overt peripheral artery disease Pregnant or nursing bleeding tendency Any contraindication of antiplatelet agent Thrombocytopenia (platelet &lt; 100,000mm3) Chronic liver disease (ALT &gt; 100 IU/L or AST &gt; 100 IU/L) or renal dysfunction (creatinine &gt; 4.0 mg/dl) Patients who can not stop to take aspirin</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Vasospastic syndrome</keyword>
	<keyword>Vascular dysregulation</keyword>
</DOC>